Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kodiak SciencesKOD -0.94%27 3-1 Month Momentum % is 15.18% as of Aug. 17, 2026. GuruFocus rates KOD with a GF Score™ of 27/100. The stock has 4 warning signs investors should review. Among 1,387 Biotechnology companies, Kodiak Sciences ranks better than 79.96% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-17), Kodiak Sciences's 3-1 Month Momentum % is 15.18%.
The industry rank for Kodiak Sciences's 3-1 Month Momentum % or its related term are showing as below:
KOD's 3-1 Month Momentum % is ranked better than 79.96% of 1387
companies
in the Biotechnology industry
Industry Median: -8.01
vs KOD: 15.18
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Kodiak Sciences 3-1 Month Momentum % Related Terms
KOD vs BEAM, TARS, VERA: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Kodiak Sciences's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kodiak Sciences 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kodiak Sciences's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Kodiak Sciences's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kodiak Sciences (KOD) has a 3-1 Month Momentum % of 15.18% as of Aug. 17, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Kodiak Sciences and its competitors. According to the industry distribution chart, Kodiak Sciences ranks #278 out of 1387 companies in the Biotechnology industry, placing it in the top 20%.
Is Kodiak Sciences' 3-1 Month Momentum % too high?
Kodiak Sciences' current 3-1 Month Momentum % is 15.18%. Based on the distribution chart, Kodiak Sciences ranks #278 out of 1387 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Kodiak Sciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Kodiak Sciences' 3-1 Month Momentum % compare to BEAM and TARS?
According to the Biotechnology industry distribution chart, Kodiak Sciences ranks #278 out of 1387 companies for 3-1 Month Momentum %. This places Kodiak Sciences in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Kodiak Sciences and its competitors. Kodiak Sciences's current 3-1 Month Momentum % is 15.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kodiak Sciences stock overvalued right now?
Kodiak Sciences (KOD) has a current 3-1 Month Momentum % of 15.18%. The current 3-1 Month Momentum % is 15.18%. Kodiak Sciences' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Kodiak Sciences (KOD), the current 3-1 Month Momentum % is 15.18% as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
27GF Score
Get the complete analysis for KOD
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KOD has been successfully added to your 
